It is time to look inward
Robert M. Merion – 28 June 2011
Need for the clarification of data in a recent meta‐analysis about cytokine gene polymorphisms and acute liver graft rejection
Fei Liu, Yonggang Wei, Bo Li, Lvnan Yan – 28 June 2011
What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma?
Christophe Duvoux, Tetsuya Kiuchi, Bernhard Pestalozzi, Ronald Busuttil, Rebecca Miksad – 28 June 2011
Markers for microvascular invasion in hepatocellular carcinoma: Where do we stand?
Annette S. H. Gouw, Charles Balabaud, Hironori Kusano, Satoru Todo, Takafumi Ichida, Masamichi Kojiro – 28 June 2011
Liver cancer: Still a long way to go
Jordi Bruix – 26 June 2011
Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents — A potentially lethal cocktail
Michael Charlton – 26 June 2011
Anti‐chemokine therapy for the treatment of hepatic fibrosis: An attractive approach
- Read more about Anti‐chemokine therapy for the treatment of hepatic fibrosis: An attractive approach
Grant A. Ramm – 26 June 2011
Copper toxicity in Wilson disease explained in a new way
Uta Merle, Wolfgang Stremmel – 26 June 2011
A glimpse at the future of hepatitis C therapy: The INFORM trial
Lei Y. Lim, Paul Y. Kwo – 26 June 2011
Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients
Caroline Barau, Aurélie Barrail‐Tran, Bogdan Hemerziu, Dalila Habes, Anne‐Marie Taburet, Dominique Debray, Valérie Furlan – 21 June 2011 – Mycophenolate mofetil (MMF) is now commonly used in pediatric liver transplant recipients, but no clear recommendations about the dosing regimen have been made for this population. The aim of this study was to determine the MMF dosage required for pediatric liver transplant recipients to achieve an area under the plasma concentration–time curve from 0 to 12 hours (AUC0‐12) for mycophenolic acid (MPA) greater than 30 mg hour/L.